Regulation of Oxidative Stress by Long Non-Coding RNAs in Vascular Complications of Diabetes

Pei-Ming Chu 1,†, Cheng-Chia Yu 2,3,4,†, Kun-Ling Tsai 5,6,* and Pei-Ling Hsieh 1,*

1 Department of Anatomy, School of Medicine, China Medical University, Taichung 404333, Taiwan; pmchu@mail.cmu.edu.tw
2 Institute of Oral Sciences, Chung Shan Medical University, Taichung 40201, Taiwan; ccyu@csmu.edu.tw
3 Department of Dentistry, Chung Shan Medical University Hospital, Taichung 40201, Taiwan
4 School of Dentistry, Chung Shan Medical University, Taichung 40201, Taiwan
5 Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; kunlingtsai@mail.ncku.edu.tw
6 Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan
* Correspondence: plhsieh@mail.cmu.edu.tw
† These authors contributed equally to this work.

Abstract: Diabetes mellitus is a well-known metabolic disorder with numerous complications, such as macrovascular diseases (e.g., coronary heart disease, diabetic cardiomyopathy, stroke, and peripheral vascular disease), microvascular diseases (e.g., diabetic nephropathy, retinopathy, and diabetic cataract), and neuropathy. Multiple contributing factors are implicated in these complications, and the accumulation of oxidative stress is one of the critical ones. Several lines of evidence have suggested that oxidative stress may induce epigenetic modifications that eventually contribute to diabetic vascular complications. As one kind of epigenetic regulator involved in various disorders, non-coding RNAs have received great attention over the past few years. Non-coding RNAs can be roughly divided into short (such as microRNAs; ~21–25 nucleotides) or long non-coding RNAs (lncRNAs; >200 nucleotides). In this review, we briefly discussed the research regarding the roles of various lncRNAs, such as MALAT1, MEG3, GAS5, SNHG16, CASC2, HOTAIR, in the development of diabetic vascular complications in response to the stimulation of oxidative stress.

Keywords: diabetic vascular complication; oxidative stress; long non-coding RNA

1. Diabetes Mellitus and Oxidative Stress

Diabetes mellitus (DM) is a chronic metabolic disorder with an increasing risk of cardiovascular diseases. It has been revealed that the global prevalence of DM is approximately 9.3% (463 million people) in 2019 and estimated to be 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [1]. There are several types of DM, including type I (insulin-dependent, juvenile DM), type II (non-insulin-dependent, adult-onset DM), and gestational DM [2]. DM has a well-established association with an increase in the likelihood of developing various complications, such as macrovascular and microvascular diseases. Macrovascular disorders include coronary heart disease, diabetic cardiomyopathy, stroke, and peripheral vascular disease, and microvascular disorders comprise diabetic nephropathy and retinopathy. Although the mortality rates owing to vascular diseases have declined, it remains one of the leading causes of death in subjects with diabetes [3,4]. Due to the rising prevalence and diverse complications, DM represents a substantial health challenge that affects the quality of life of patients and elevates the demands on health services.

Oxidative stress refers to the enhanced intracellular levels of reactive oxygen species (ROS), such as superoxide anion (O2·−), hydrogen peroxide (H2O2), and hydroxyl radicals (OH·), that are not fully eliminated by certain antioxidant enzymes, such as superoxide...
dismutases (SOD), and then induce damage to lipids, proteins, and DNA. To regulate the cellular redox balance and protective antioxidant system, the nuclear factor erythroid 2-related factor 2 (Nrf2) and its target genes are activated. Under physiological conditions, Kelch-like ECH-associated protein 1 (Keap1) is responsible for the cytosolic sequestration of Nrf2. Under stressful conditions, Nrf2 will be released from Keap1 and translocate into the nucleus where it binds to the antioxidant response element (ARE) sequence and increases the transcription of antioxidant enzymes, such as heme oxygenase-1 (HO-1) [5]. On the other hand, the hyperglycemia-induced tissue injury has been shown to be mediated by the following mechanisms, including the increased flux of glucose and other sugars through the polyl pathway, the increased production of advanced glycation end products (AGEs), activation of protein kinase C (PKC) isoforms, increased hexosamine pathway flux and consequent over-modification of proteins by N-acetylglucosamine, and these pathways are all activated by the hyperglycemia-induced mitochondrial superoxide production by inhibiting GAPDH [6]. Accordingly, the downregulation of hyperglycemia-associated oxidative stress will aid in the better control of diabetic complications.

2. Long Non-Coding RNA

Emerging evidence has suggested that non-coding RNAs may function as crucial modulators in the response to oxidative stress [7]. Non-coding RNAs constitute the vast majority of human transcripts and are classified into different groups based on their length and function. It usually can be categorized into short (such as microRNAs; ~21–25 nucleotides) or long non-coding RNAs (lncRNAs; >200 nucleotides). Unlike microRNAs which exert their regulatory capacity through binding to the 3′ untranslated region (UTR) of their target genes, the embodiment of the lncRNAs function includes a variety of ways, such as serving as scaffolds, molecular signals, guides, or decoys [8]. Recently, more and more lncRNAs have been discovered to shape gene expression by titrating microRNAs with their microRNAs response elements (MREs), and they are called competing endogenous RNAs (ceRNAs) [9]. These ceRNAs act as natural microRNAs sponges and may bind multiple microRNA molecules to co-regulate each other.

Aberrant expression of lncRNAs has been observed in various diseases, including in samples of DM patients [10]. Besides, lncRNAs are involved in the development of insulin resistance by regulating lipid and carbohydrate metabolism, inflammatory process, and oxidative stress [11]. Of note, a variety of lncRNAs have functional interactions with microRNAs by serving as molecular sponges to affect several aspects of cellular responses to oxidative stress. In this review, we discuss the roles of multiple lncRNAs in a number of diabetic complications and how they modulate oxidative stress insult. We aim to provide better insight into the association between the dysregulation of lncRNAs and the accumulation of oxidative stress in disease progression. In the following sections, we summarize various lncRNAs (e.g., HOTAIR, MALAT1, MEG3, GAS5, SNHG16, and CASC2) that contribute to the development of these diabetic vascular complications through regulation of oxidative stress (Figure 1).
Figure 1. Roles and functions of the listed lncRNAs in the regulation of oxidative stress-related complications.

3. Diabetic Nephropathy

The deterioration of kidney function due to DM is called diabetic nephropathy, which has been known as the most common cause of end-stage renal disease (ESRD) [12]. The cellular components of the kidney, such as glomerular endothelial cells, mesangial cells, podocytes, and tubular epithelial cells, are potential targets of hyperglycemic injury. Patients with diabetic nephropathy may experience glomerular hyperfiltration, progressive albuminuria, reduction in glomerular filtration rate, the elevation of arterial blood pressure and fluid retention, and ultimately, ESRD. Numerous pathways have been revealed to be activated during the course of diabetic nephropathy, such as the renin-angiotensin-aldosterone system; the pro-fibrotic and inflammatory cytokines, such as transforming growth factor-β (TGF-β) and tumor necrosis factor-α (TNF-α); various kinases such as PKC; and oxidative stress mediators, such as nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) [13].

3.1. HOTAIR

HOX antisense intergenic RNA (HOTAIR) is a 2.2 kilobase non-coding RNA and one of the first described lncRNA [14]. It is located in the homeobox C gene (HOXC) cluster between the HOXC11 and HOXC12 genes on human chromosome 12q13.13. HOTAIR is an example of scaffold lncRNAs as it interacts with Polycomb Repressive Complex 2 (PRC2), which methylates histone H3 on lysine 27 to induce gene repression [14]. HOTAIR also exerts its transcriptional effect across chromosomes in trans, and has been found to promote breast cancer metastasis [15]. HOTAIR is expressed in normal adult human kidney tissue, including glomerular podocytes. It also has been found to be upregulated in the kidneys of humans and mice with diabetes [16]. Nevertheless, Majumder et al. showed that knockout of HOTAIR from podocytes has minimal effect on the glomerular injury in diabetic mice [16]. They concluded that the dysregulation of HOTAIR in diabetes may be a bystander in diabetic kidney disease instead of a contributor.
3.2. MALAT1

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also known as NEAT2, is an 8.5 kilobase lncRNA located within the human chromosome 11q13 [17]. As its name suggests, MALAT1 serves as an oncogene in various types of cancers, and it has been found to be increased in kidney cortices from C57BL/6 mice with streptozocin (STZ)-induced type I DM [18]. In the work by Hu et al., they showed that there is a feedback regulation between MALAT1 and β-catenin, which may implicate in the high glucose-induced podocyte damage [18]. Likewise, the circulating expression of MALAT1 is upregulated in patients with diabetic nephropathy, and there is a negative correlation between MALAT1 and the anti-oxidant enzyme, SOD [19]. It has been shown that the silencing of MALAT1 downregulates the oxidative stress and inflammatory reaction in the renal tissues of diabetes (db/db) mice [20]. Moreover, MALAT1 has been demonstrated to contribute to the podocyte injury by reducing miR let-7f and increasing krippel-like factor 5 (KLF5) [20]. KLF5 has been found to induce oxidative stress via directly binding on NADPH oxidase (NOX) promoter, which elevates the expression of NOX4 in AC16 human cardiomyocyte cells [21]. Hence, MALAT1 may also generate oxidative stress in diabetic renal tissues by regulating KLF5/NOX4 signaling. Additionally, it has been demonstrated that the expression levels of Nrf2 and HO-1 are both elevated in mouse podocyte MPC-5 cells with MALAT1-3 siRNA under high glucose conditions [22]. As mentioned above, Nrf2 is a redox-sensitive transcription factor, which regulates the expression of various antioxidant enzymes via ARE [23]. As such, another avenue for MALAT1 to generate oxidative stress is via modulation of Nrf2/HO-1 signaling.

3.3. MEG3

Maternally expressed gene 3 (MEG3), also known as gene trap locus 2 (Gtl2), is located at chromosome 14q32.3 within Dlk1-Dio3 locus [24,25]. Knockdown of MEG3 has been found to potentiate insulin resistance and impair glucose homeostasis in diet-induced obese mice [26]. It has been shown that the expression of MEG3 is increased in podocytes of the STZ-induced mice, high glucose-stimulated human podocytes and mesangial cells, and serum of patients with diabetic nephropathy [27–29]. Moreover, knockdown of MEG3 in podocytes alleviates albuminuria, renal dysfunction, glomerular injury, and podocyte mitochondrial fission in DM mice [27]. The in vitro experiment shows that MEG3 promotes mitochondrial fission in podocytes by regulation of dynamin-1-like protein (drp1) and its translocation to mitochondria [27], which may cause oxidative stress and cell damage in DM [30,31]. MEG3 has been proven to interact with several microRNAs, such as miR-181a [28] and miR-145 [29], that are associated with the regulation of oxidative stress [32,33]. However, one study with controversial findings suggests that MEG3 expression is decreased in renal tissues of patients with DN and podocytes treated with high glucose [34]. They demonstrated that MEG3 protects against the high glucose-induced ROS production and podocyte injury via inactivating Wnt/β-catenin signaling [34].

3.4. GAS5

Growth arrest-specific 5 (GAS5) is located at 1q25.1 and was originally identified in a study aimed to screen for novel tumor suppressor genes expressed at high levels during growth arrest [35]. It has been shown that GAS5 expression is reduced in high glucose-induced proximal tubular cells [36] or mesangial cells [37]. In the kidney tissues of type 2 DM with diabetic nephropathy, GAS5 is also downregulated compared with that in patients without diabetic nephropathy [37]. Nevertheless, the animal studies seem to exhibit inconsistent results. It has been shown that GAS5 is increased in kidneys of the high-fat diet (HFD)/STZ-induced diabetic mice and reported to exacerbate renal tubular epithelial fibrosis [38]. However, other studies demonstrate that the expression of GAS5 in kidney tissues of STZ-induced diabetic nephropathy rats is decreased, which may alleviate renal fibrosis in diabetic nephropathy [37,39]. In addition to suppression of matrix
metalloproteinase 9 via recruiting enhancer of zeste homolog 2 (EZH2) [39]. GAS5 also improves the high glucose-induced renal damage by reduction of oxidative stress.

It has been shown that GAS5 can serve as a ceRNA to sponge miR-221 via both directly targeting and Ago2-dependent manner. The work by Ge et al. demonstrates that miR-221 is able to downregulate the proliferation and fibrosis-related proteins by targeting sirtuin1 (SIRT1) [37]. Given that SIRT1 is a protein deacetylase that helps to antagonize oxidative stress in various disease conditions, including diabetes [40,41], it is reasonable to postulate that upregulation of GAS5 may downregulate the increased oxidative stress in diabetic nephropathy. This assumption proves to be correct as another study demonstrates that GAS5 mitigates oxidative stress in high-glucose-stimulated renal tubular cells [36]. They show overexpression of GAS5 reverses the increased ROS and oxidative stress indicator, malondialdehyde (MDA) as well as the anti-oxidant SOD in high-glucose-stimulated cells via directly binding to miR-452-5p [36].

3.5. SNHG16

The small nucleolar RNA host genes (SNHGs) are a group of lncRNAs, including SNHG1, SNHG3, SNHG5, SNHG6, SNHG7, SNHG12, SNHG15, SNHG16, SNHG20, that are found to exhibit oncogenic roles in a variety of malignancies [42]. SNHG16, also known as non-coding RNA, expressed in aggressive neuroblastoma (ncRAN), is located at chromosome 17q25.1 [43]. It has been revealed that SNHG16 is overexpressed in the serum of diabetic nephropathy patients, high glucose-treated podocytes [44], and mesangial cells [45]. In the renal cortex of db/db mice, SNHG16 is markedly increased as well [45]. It has been shown that SNHG16 is involved in the proliferation of mesangial cells and fibrogenesis via modulating miR-141-3p [45]. Besides, He et al. show that SNHG16 aggravates the high glucose-induced podocytes injury, including cell viability, ROS production, and apoptosis, through upregulation of Krüppel-like factor 9 (KLF9) via sponging miR-106a [44]. KLF9 has been known to bind to the promoters and affects the expression of various genes involved in the metabolism of ROS, such as the anti-oxidant defense gene thioredoxin reductase 2, and Nrf2 can exaggerate oxidative injury through induction of KLF9 [46]. Therefore, SNHG16 seems to contribute to diabetic nephropathy via KLF9-induced oxidative stress by directly interfering with miR-106a.

3.6. CASC2

Cancer susceptibility candidate 2 (CASC2) is located at chromosome 10q26 in humans and was first discovered in 2004 by Baldinu et al. [47]. CASC2 acts as a tumor suppressor in various types of cancers [48] and its expression level is reduced in the serum of diabetic nephropathy patients [49], tissues in db/db diabetic mouse, and high glucose-treated human renal mesangial cells [50] and podocyte cells [49–52]. Upregulation of CASC2 has been shown to attenuate the progression of diabetic nephropathy via various pathways. For instance, it has been shown that overexpression of CASC2 inhibits apoptosis of podocyte cells and reduces the phosphorylation level of c-Jun N-terminal kinase 1 (JNK1) [49]. CASC2 also mitigates cell apoptosis, inflammatory factor release, and fibrosis progression via miR-144/suppressor of cytokine signaling 2 (SOCS2) axis [50]. Although the role of SOCS2 in the regulation of oxidative stress in diabetic nephropathy has not been fully elucidated, SOCS2 has been revealed to modulate ROS formation in hepatocytes [53]. Besides, upregulation of CASC2 downregulates the high glucose-induced proliferation, extracellular matrix deposition and oxidative stress of human mesangial cells via miR-133b/forkhead box P1 (FOXP1) axis [52]. It has been demonstrated that overexpression of FOXP1 reduces ROS level through downregulation of Akt/mTOR signaling and the expression of two major ROS-producing enzymes, NOX2 and NOX4 [54].

4. Diabetic Cardiomyopathy and Vascular Complications

Diabetic cardiomyopathy refers to the presence of abnormal myocardial structure or performance in the absence of other risk factors, such as coronary artery disease, hyperten-
sion, and significant valvular disease, in individuals with DM [55]. It is characterized by left ventricular hypertrophy, dysfunctional remodeling, diastolic and systolic dysfunction, and eventually heart failure [56]. Among various mechanisms that are implicated in the development of diabetic cardiomyopathy, it has been demonstrated that H19/miR-675 axis modulates apoptosis of cardiomyocytes by affecting voltage-dependent anion channel 1 (VDAC1) [57]. Moreover, the increased ROS has been shown to impair cardiac structure by directly damaging myocytes. For example, it has been demonstrated that short-term exposure to \( \text{H}_2\text{O}_2 \) of rat ventricular myocytes results in a progressive decrease in cell shortening followed by diastolic arrest, which may be due to oxidative modification of sarcoplasmic reticulum \( \text{Ca}^{2+} \)-ATPase (SERCA) and the \( \text{Na}^+ / \text{Ca}^{2+} \) exchanger (NCX) [58].

Besides, increased cardiomyocyte NOX2 activity has been observed in diet-induced obese female mice with cardiac diastolic dysfunction [59].

4.1. HOTAIR

Although HOTAIR has been considered as an oncogene in various types of cancers [60], it seems to possess a protective effect in patients with diabetic cardiomyopathy. It has been reported that HOTAIR expression is reduced in myocardial tissues and serum of diabetic cardiomyopathy patients [61]. Moreover, HOTAIR has been proven to increase the viability of cardiomyocytes, possibly through activation of the PI3K/Akt pathway [61]. Various studies have shown that the PI3K-Akt pathway is associated with oxidative stress generation in numerous diabetic impairments [62,63]. Similar findings are presented in the STZ-induced type 1 DM model. In diabetic mice hearts, the HOTAIR expression is significantly decreased. Moreover, knockdown of HOTAIR in the high glucose-treated cardiomyocytes H9c2 cells leads to increased oxidative injury, inflammation, and apoptosis. Gao et al. show that HOTAIR acts as a molecular sponge of miR-34a, which subsequently activates the expression of SIRT1 by inhibiting the repression from miR-34a [64]. Overexpression of HOTAIR also has been demonstrated to inhibit the expression of miR-126, which increases the expression of SIRT1 by regulating Klotho in aortic smooth muscle cells [65].

4.2. MEG3

MEG3 has been found to be overexpressed in high glucose-treated cardiomyocytes and serve as a ceRNA for miR-145 to induce apoptosis by upregulating the expression of programmed cell death 4 (PDCD4) [66]. Given that miR-145 has been suggested to mitigate the high glucose-induced oxidative stress and inflammation in retinal endothelial cells [67], it is tempting to assume that MEG3 may enhance the accumulation of oxidative stress via directly binding to miR-145. Of note, MEG3 deficiency has been shown to cause impairment of insulin signaling through induction of cellular senescence in the hepatic endothelium. It has been revealed that the expression of endothelial MEG3 is elevated in obesity, and knockdown of MEG3 causes cellular senescence in human umbilical vein endothelial cells (HUVECs) and hepatic endothelium in obese mice [26]. In addition, MEG3 knockdown upregulates the level of superoxide and other free radicals in HUVECs using MitoSOX staining and electron paramagnetic resonance spectroscopy. The work by Cheng et al. demonstrated that lacking MEG3 decreases the basal mitochondrial \( \text{O}_2 \) consumption rate and the maximal respiration capacity without affecting the extracellular acidification rate [26].

5. Diabetic Retinopathy and Diabetic Cataract

Diabetic retinopathy is one of the most common causes of blindness among adults and the elderly. Nearly all patients with type I DM and more than 60% of patients with type II DM eventually have diabetic retinopathy [68]. There are two kinds of diabetic retinopathy, non-proliferative and proliferative diabetic retinopathies. Non-proliferative diabetic retinopathy is characterized by vascular closure, preceded by increased vascular permeability. As the disease progresses into proliferative diabetic retinopathy, abnormal
growth of blood vessels on the retina in response to the ischemia may cause blood leak into the vitreous which leads to the subsequent macular edema [68]. It has been shown that lncRNA H19 inhibits the endothelial-mesenchymal transition of retinal endothelial cells [69] and regulates inflammation of retinal epithelial cells [70] in diabetic retinopathy. Luo et al. showed that H19 can sponge miR-93 and modulate X-box binding protein 1 (XBP1) to downregulate pro-inflammatory cytokines [70]. On the other hand, several studies have demonstrated that supplements of anti-oxidant enzymes could attenuate the progression of the diabetic retina [71] and inhibit the activation of redox-sensitive nuclear transcriptional factors [72]. In the following sections, we summarized how lncRNAs are involved in the regulation of abnormal retinal metabolism in diabetes.

5.1. HOTAIR

It is reported that there is a significant increase in serum HOTAIR of diabetic retinopathy patients, and the upregulation of HOTAIR can be used to discriminate diabetic retinopathy from nondiabetic retinopathy [73]. One of the in vitro studies supports this finding and shows that high glucose markedly augments the expression of HOTAIR in human retinal endothelial cells, which increases oxidative damage, endothelial cell junction disruptions, and mitochondrial aberrations [74]. Another study demonstrated that HOTAIR can directly interact with lysine-specific histone demethylase 1 (LSD1) using retinal endothelial cells [75]. It has been shown that high glucose enhances the binding of LSD1 and Sp1 at SOD2 (MnSOD), and knockdown of LSD1 with siRNA improves the high glucose-induced H3K4 demethylation at SOD2 to increase SOD2 gene expression [76]. These findings suggest that HOTAIR may regulate the antioxidant capacity in the development of diabetic retinopathy by affecting the epigenetic modification of SOD2.

5.2. MALAT1

The aberrant upregulation of MALAT1 has been reported in the diabetic retinas using clinical samples, STZ-induced type I DM mice [77], and db/db type 2 DM mice [78]. In the MALAT1 null mice, the expression of Nrf2 and antioxidant genes including Nqo1 and Cat is upregulated with concomitant downregulation of ROS and ROS-generated protein carbonylation in hepatocyte and islets [79]. Chen et al. demonstrated that MALAT1 interacts with Nrf2 and regulates insulin resistance by modulation of JNK activity and phosphorylation of Akt [79]. In diabetic retinopathy, MALAT1 also plays an integral part in the regulation of the Keap1-Nrf2-antioxidant defense system. It has been revealed that high glucose elevates the expression of MALAT1 by increasing Sp1 transcription factor binding at the MALAT1 promoter. Furthermore, the increased MALAT1 recruits more Sp1 at the Keap1 promoter and activates its transcription [80]. Given that Keap1 quenches Nrf2 and inhibits its transcriptional activity, the transcription of the antioxidant response enzymes, such as HO1 and SOD2, are also decreased [80].

Another study showed that MALAT1 competitively binds to miR-125b against vascular endothelial-cadherin, which may promote neovascularization in diabetic retinopathy [81]. Although there is a lack of direct evidence showing MALAT1/miR-125b axis affects oxidative stress, it is reported that ROS production in neuronal PC12 cells is remarkably upregulated upon transfection with the miR-125b-5p mimic under high-glucose conditions [82]. Whether the interaction between MALAT1 and miR-125b contributes to the redox homeostasis in diabetic retinopathy is worthy of investigation.

Besides, it has been shown that knockdown of MALAT1 ameliorates the retinal function and retinal vessel impairment in diabetic rats. Moreover, the cell viability, migration and tube formation, retinal inflammation, oxidative stress in retinal endothelial cells are improved. The work by Liu et al. suggests that MALAT1 knockdown prevents the hyper-proliferation of retinal endothelial cells through p38 mitogen-activated protein kinase (MAPK) signaling [78]. A similar finding is reported in diabetic cataracts. It is revealed that MALAT1 is aberrantly expressed in the anterior lens capsule tissues of patients with diabetic cataracts and high glucose-treated human lens epithelial cells [83]. Moreover,
knockdown of MALAT1 also reverses the high glucose-induced oxidative stress, including a higher level of oxidative stress indicator MDA and lower levels of anti-oxidant SOD and glutathione peroxidase (GSH-PX) via the p38MAPK pathway [83]. Taken together, MALAT1 seems to modulate ROS via regulation of the Keap1-Nrf2 axis and p38MAPK pathway.

5.3. MEG3

It has been shown that MEG3 expression level is markedly downregulated in the fibrovascular membranes of diabetic patients and retinas of STZ-induced diabetic mice [84] as well as the high glucose-treated Müller cells, the principal glial cell of the retina [85]. MEG3 has been shown to act as a ceRNA for miR-204 and counteract its suppression of SIRT1 [85]. The subsequent work by Tu et al. demonstrated that deacetylation of SIRT1 target genes, such as forkhead box o1 (FOXO1) and nuclear factor kappa B (NF-κB) subunit p65, eventually leads to the reduction of oxidative stress and inflammation in high glucose-treated Müller cells [86]. In human retinal pigment epithelium cells, MEG3 has been demonstrated to increase Nrf2 by sequestering miR-93, which suppresses high glucose-induced apoptosis and inflammation [87]. Similarly, MEG3 can alleviate high glucose-associated apoptosis and inflammation through inhibiting NF-κB signaling via impeding the interaction between miR-34a and SIRT1 in retina epithelial cells [88]. These results show that MEG3 may be beneficial to treat diabetic retinopathy by suppression of oxidative stress and inflammation.

5.4. SNHG16

Several studies indicate that SNHG16 aggravates diabetic retinopathy. It has been demonstrated that SNHG16 is markedly upregulated in H2O2, high glucose, or AGE-treated human retinal microvascular endothelial cells (hRMECs) [89,90]. Cai et al. show that an increase of SNHG16 in the high glucose-stimulated hRMECs promotes the proliferative diabetic retinopathy-related abnormalities in cell proliferation, migration, and angiogenesis via modulation of miR-146a-5p/interleukin-1 receptor-associated kinase 1 (IRAK1) and miR-7-5p/insulin receptor substrate 1 (IRS1) to activate NF-κB and PI3K/AKT signaling pathways, respectively [89]. Another study reveals that SNHG16 modulates the expression of E2F transcription factor-1 (E2F1) by sponging miR-20a-5p, which increases apoptosis of hRMECs [91]. E2F1 has been shown to regulate oxidative metabolism [92] and mediate the direct effects of high glucose on retinal neurons, glial cells, and blood vessels [93]. Besides, SNHG16 also increases oxidative stress-induced pathological angiogenesis in hRMECs through modulating the miR-195/ mitofusin 2 (mfn2) axis [90]. Mfn2 implicates in the control of mitochondrial membrane fusion and is downregulated in the diabetic retina [94]. It has been revealed that overexpression of mfn2 attenuates the glucose-induced accumulation of mitochondrial ROS [94]. As such, these results suggest that the high glucose-inhibited SNHG16 may contribute to the increased oxidative stress in DR via miR-20a-5p/E2F1 or miR-195/mfn2 axes. The aforementioned lncRNAs and the associated mechanisms are listed in Table 1.

| Diabetic Complications       | LncRNA | Expression Level | Cells or Tissues                              | Interacting Factors/Pathways                      | Ref. |
|------------------------------|--------|------------------|----------------------------------------------|-------------------------------------------------|------|
| Diabetic Nephropathy         | MALAT1 | Upregulated      | Kidney cortices in STZ-injected C57BL/6 mice | SOD                                             | [18] |
| Diabetic Nephropathy         | MALAT1 | Upregulated      | Patients with DN                             | KLFl                                            | [19] |
| Diabetic Nephropathy         | MALAT1 | Upregulated      | Mouse podocyte MPC-5 cells                   | Nrf2/HO-1 signaling                              | [20] |
| Diabetic Nephropathy         | MALAT1 | Upregulated      | Mouse podocyte MPC-5 cells                   | drp1                                            | [22] |
| Diabetic Nephropathy         | MEG3   | Upregulated      | Podocytes of STZ-induced mice                | miR-181a                                        | [27] |
| Diabetic Nephropathy         | MEG3   | Upregulated      | HG-treated mesangial cells                   | miR-145                                         | [28] |
| Diabetic Nephropathy         | MEG3   | Upregulated      | Serum of patients with DN                    | Wnt/β-catenin signaling                          | [29] |
| Diabetic Nephropathy         | MEG3   | Downregulated    | Renal tissues of patients with DN and HG-treated podocytes |                                              | [34] |
Table 1. Cont.

| Diabetic Complications | LncRNA | Expression Level | Cells or Tissues | Interacting Factors/Pathways | Ref. |
|------------------------|--------|------------------|------------------|-----------------------------|------|
| Diabetic Nephropathy   | GAS5   | Downregulated    | HG-induced proximal tubular cells | mir-452-5p/SOD axis          | [36] |
| Diabetic Nephropathy   | GAS5   | Downregulated    | HG-treated mesangial cells | miR-221/SIRT1 axis          | [37] |
| Diabetic Nephropathy   | GAS5   | Upregulated      | Kidneys of the HFD/STZ-induced diabetic mice | miR-106a/KLF9 axis | [44] |
| Diabetic Nephropathy   | SNHG16 | Upregulated      | Serum of DN patients and HG-treated podocytes | miR-133b/FOXP1 axis | [52] |
| Diabetic Nephropathy   | SNHG16 | Upregulated      | HG-treated mesangial cells | miR-221/SIRT1 axis | [37] |
| Diabetic Nephropathy   | CASC2  | Downregulated    | Serum of DN patients and podocyte cells | miR-106a/KLF9 axis | [44] |
| Diabetic Nephropathy   | CASC2  | Downregulated    | Tissues in db/db diabetic mouse and HG-treated mesangial cells and podocytes | miR-133b/FOXP1 axis | [52] |
| Diabetic Cardiomyopathy| HOTAIR | Downregulated    | Myocardial tissues and serum of diabetic cardiomyopathy patients | miR-34a/SIRT1 axis | [64] |
| Diabetic Cardiomyopathy| HOTAIR | Downregulated    | Myocardial tissues and serum of diabetic cardiomyopathy patients | miR-34a/SIRT1 axis | [64] |
| Diabetic Retinopathy   | MEG3   | Upregulated      | HG-treated cardiomycocytes | miR-145 | [66] |
| Diabetic Retinopathy   | HOTAIR | Upregulated      | HG-treated human retinal endothelial cells | SIRT1 axis | [74] |
| Diabetic Retinopathy   | HOTAIR | Upregulated      | HG-treated human retina endothelial cells | LSD1/MnSOD axis | [75,76] |
| Diabetic Retinopathy   | MALAT1 | Upregulated      | Diabetic retinas using clinical samples, STZ-induced type 1 DM mice | Keap1-Nrf2 axis | [78] |
| Diabetic Retinopathy   | MALAT1 | Upregulated      | db/db type 2 DM mice | Keap1-Nrf2 axis | [78] |
| Diabetic Retinopathy   | MALAT1 | Upregulated      | HG-treated human lens epithelial cells | Keap1-Nrf2 axis | [78] |
| Diabetic Retinopathy   | MEG3   | Downregulated    | HG-treated Müller cells | Keap1-Nrf2 axis | [78] |
| Diabetic Retinopathy   | MEG3   | Upregulated      | HG-treated retinal pigment epithelium cells | miR-204/SIRT1 axis | [85] |
| Diabetic Retinopathy   | MEG3   | Upregulated      | HG-treated retina epithelial cells | miR-34a/SIRT1 axis | [88] |
| Diabetic Retinopathy   | SNHG16 | Upregulated      | HG-treated retinal microvascular endothelial cells | miR-195/mfn2 axis | [90] |
| Diabetic Retinopathy   | SNHG16 | Upregulated      | HG-treated retinal microvascular endothelial cells | miR-20a-5p/E2F1 axis | [91] |

Abbreviation: STZ, streptozotocin; DN, diabetic nephropathy; SOD, superoxidase dismutase; KLF5/9, Kruppel-like factor 5/9; Nrf2, nuclear factor erythroid 2-related factor 2; HO-1, heme oxygenase-1; Drp1, dynamin-related protein 1; HG, high glucose; SIRT1, Sir2uin 1; HFD, high-fat diet; FOXP1, forkhead box protein 1; LSD1, lysine-specific demethylase 1; Keap1, Kelch-like ECH-associated protein 1; SPI, specificity protein 1; Mfn2, mitofusin-2; E2F1, E2F transcription factor 1.

6. Conclusions

DM is a multifactorial disorder with a wide range of vascular complications. As shown in Table 1, the aberrant expression of lncRNAs may act as potential biomarkers for the diagnosis and prognosis of macrovascular and microvascular diseases. We showed that these lncRNAs can directly modulate the anti-oxidant pathways (such as Nrf2/HO-1 signaling) and enzymes (such as SOD). Besides, cumulative research suggests that numerous lncRNAs can regulate the pathogenesis of diabetic vascular complications through interacting with several microRNAs. Further research is needed to investigate if targeting these lncRNAs can effectively alleviate the progression of diabetic vascular complications.

Author Contributions: Conceptualization, P.-L.H.; writing—original draft preparation, P.-M.C., C.-C.Y. and P.-L.H.; writing—review and editing, P.-M.C., C.-C.Y. and K.-L.T. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by China Medical University (CMU110-MF-65).
**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. *Diabetes Res. Clin. Pract.* 2019, 157, 107843.

2. Yang, J.S.; Lu, C.C.; Kuo, S.C.; Hsu, Y.M.; Tsai, S.C.; Chen, S.Y.; Chen, Y.T.; Lin, Y.J.; Huang, Y.C.; Chen, C.J.; et al. Autophagy and its link to type II diabetes mellitus. *Biomedicine* 2017, 7, 8. [CrossRef] [PubMed]

3. Pearson-Stuttard, J.; Bennett, J.; Cheng, Y.J.; Vamos, E.P.; Cross, A.J.; Ezzati, M.; Gregg, E.W. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: An epidemiological analysis of linked primary care data. *Lancet Diabetes Endocrinol.* 2021, 9, 165–173. [CrossRef]

4. Gregg, E.W.; Cheng, Y.J.; Srinivasan, M.; Lin, J.; Geiss, L.S.; Albright, A.L.; Imperatore, G. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: An epidemiological analysis of linked national survey and vital statistics data. *Lancet* 2018, 391, 2430–2440. [CrossRef]

5. Nguyen, T.; Nioi, P.; Pickett, C.B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. *J. Biol. Chem.* 2009, 284, 13291–13295. [CrossRef] [PubMed]

6. Brownlee, M. The pathology of diabetic complications: A unifying mechanism. *Diabetes* 2005, 54, 1615–1625. [CrossRef] [PubMed]

7. Ghafouri-Fard, S.; Shoorei, H.; Taheri, M. Non-coding RNAs are involved in the response to oxidative stress. *Biomed. Pharmacother.* 2020, 127, 110228. [CrossRef]

8. Wang, K.C.; Chang, H.Y. Molecular mechanisms of long noncoding RNAs. *Mol. Cell* 2011, 43, 904–914. [CrossRef]

9. Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P.P. A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? *Cell* 2011, 146, 353–358. [CrossRef]

10. Dieter, C.; Lemos, N.E.; Corrêa, N.R.F.; Assmann, T.S.; Crispim, D. The Impact of IncRNAs in Diabetes Mellitus: A Systematic Review and In Silico Analyses. *Front. Endocrinol.* 2021, 12, 602597. [CrossRef]

11. Tello-Flores, V.A.; Beltrán-Anaya, E.O.; Ramírez-Vargas, M.A.; Esteban-Casales, B.E.; Navarro-Tito, N.; Alarcón-Romero, L.D.C.; Luciano-Villa, C.A.; Ramírez, M.; Del Moral-Hernández, Ó.; Flores-Alfar, E. Role of Long Non-Coding RNAs and the Molecular Mechanisms Involved in Insulin Resistance. *Int. J. Mol. Sci.* 2021, 22, 7256. [CrossRef]

12. Molitch, M.E.; DeFronzo, R.A.; Franz, M.J.; Keane, W.F.; Mogensen, C.E.; Parving, H.H.; Steffes, M.W. Nephropathy in diabetes. *Diabetes Care* 2004, 27 (Suppl. 1), S79–S83.

13. Arora, M.K.; Singh, U.K. Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update. *Vasc. Pharmacol.* 2013, 58, 259–271. [CrossRef]

14. Rinn, J.L.; Kertesz, M.; Wang, J.K.; Squazzo, S.L.; Xu, X.; Brugmann, S.A.; Goodnough, L.H.; Helms, J.A.; Farnham, P.J.; Segal, E.; et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell* 2007, 129, 1311–1323. [CrossRef]

15. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; Argani, P.; Rinn, J.L.; et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 2010, 464, 1071–1076. [CrossRef]

16. Majumder, S.; Hadden, M.J.; Thieme, K.; Batchu, S.N.; Niveditha, D.; Chowdhury, S.; Yerra, V.G.; Advani, S.L.; Bowskil, B.B.; Liu, Y.; et al. Dysregulated expression but redundant function of the long non-coding RNA HOTAIR in diabetic kidney disease. *Diabetologia* 2019, 62, 2129–2142. [CrossRef]

17. Ji, P.; Diederichs, S.; Wang, W.; Böing, S.; Metzger, R.; Schneider, P.M.; Tidow, N.; Brandt, B.; Buerger, H.; Bulk, E.; et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. *Oncogene* 2003, 22, 8031–8041. [CrossRef]

18. Hu, M.; Wang, R.; Li, X.; Fan, M.; Lin, J.; Zhen, J.; Chen, L.; Lv, Z. lncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose-induced podocyte injury via its interplay with β-catenin. *J. Cell. Mol. Med.* 2017, 21, 2732–2747. [CrossRef]

19. Zhou, L.J.; Yang, D.W.; Ou, L.N.; Guo, X.R.; Wu, B.L. Circulating Expression Level of LncRNA Malat1 in Diabetic Kidney Disease Patients and Its Clinical Significance. *J. Diabetes Res.* 2020, 2020, 4729019. [CrossRef]

20. Zhang, H.; Yan, Y.; Hu, Q.; Zhang, X. LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy. *Life Sci.* 2021, 266, 118794. [CrossRef]

21. Kyriazis, I.D.; Hoffman, M.; Gaignebet, L.; Lucchese, A.M.; Markopoulou, E.; Palioura, D.; Wang, C.; Bannister, T.D.; Christofidou-Solomidou, M.; Oka, S.J.; et al. KLF5 Is Induced by FOXO1 and Causes Oxidative Stress and Diabetic Cardiomyopathy. *Circ. Res.* 2021, 128, 335–357. [CrossRef]

22. Zuo, Y.; Chen, L.; He, X.; Ye, Z.; Li, L.; Liu, Z.; Zhou, S. Atorvastatin Regulates MALAT1/miR-200c/NRF2 Activity to Protect Against Podocyte Pyroptosis Induced by High Glucose. *Diabetes Metab. Syndr. Obes.* 2021, 14, 1631–1645. [CrossRef]
23. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; et al. An Nrfl2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem. Biophys. Res. Commun.* 1997, 236, 313–322. [CrossRef]

24. Schmidt, J.V.; Matteson, P.G.; Jones, B.K.; Guan, X.J.; Tilghman, S.M. The Dlk1 and Gtl2 genes are linked and reciprocally imprinted. *Genes Dev.* 2000, 14, 1997–2002. [CrossRef]

25. Kagami, M.; Sekita, Y.; Nishimura, G.; Irie, M.; Kato, F.; Okada, M.; Yamamori, S.; Kishimoto, H.; Nakayama, M.; Tanaka, Y.; et al. Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes. *Nat. Genet.* 2008, 40, 237–242. [CrossRef]

26. Cheng, X.; Ali, M.S.S.H.; Moran, M.; Viana, M.P.; Schlichte, S.L.; Zimmerman, M.C.; Khalimonchuk, O.; Feinberg, M.W.; Sun, X. Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and insulin signaling by inducing cellular senescence of hepatic endothelium in obesity. *Redox Biol.* 2021, 40, 101863. [CrossRef]

27. Deng, Q.; Wen, R.; Liu, S.; Chen, X.; Song, S.; Li, X.; Su, Z.; Wang, C. Increased long noncoding RNA maternally expressed gene 3 contributes to podocyte injury induced by high glucose through regulation of mitochondrial fission. *Cell Death Dis.* 2020, 11, 814. [CrossRef]

28. Zha, F.; Qu, X.; Tang, B.; Li, J.; Wang, Y.; Zheng, P.; Ji, T.; Zhu, C.; Bai, S. Long non-coding RNA Meg3 promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis. *Aging 2019*, 11, 3716–3730. [CrossRef]

29. Li, J.; Jiang, X.; Duan, L.; Wang, W. Long non-coding RNA GAS5 exacerbates renal tubular epithelial cell injury in diabetic nephropathy by inactivating Wnt/β-catenin signaling. *Cell Death Dis.* 2019, 10, 2609–2617. [CrossRef]

30. Sharma, K.; Karl, B.; Mathew, A.V.; Gangoiti, J.A.; Wassel, C.L.; Saito, R.; Pu, M.; Sharma, S.; You, Y.H.; Wang, L.; et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. *J. Am. Soc. Nephrol.* 2013, 24, 1901–1912. [CrossRef]

31. Shenouda, S.M.; Widlansky, M.E.; Chen, K.; Xu, G.; Holbrook, M.; Tabit, C.E.; Hamburg, N.M.; Frame, A.A.; Caiano, T.L.; Kluge, M.A.; et al. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. *Circulation* 2011, 124, 444–453. [CrossRef]

32. Zheng, W.; Li, T.; Wei, J.; Zhang, Y.; Zuo, Q.; Lin, Y. Identification of miR-145 as a regulator of the cardiomyocyte inflammatory response and oxidative stress under hyperglycemia. *Exp. Ther. Med.* 2021, 21, 467. [CrossRef]

33. Zhou, B.; Li, C.; Qi, W.; Zhang, Y.; Zhang, F.; Wu, J.X.; Hu, Y.N.; Wu, D.M.; Liu, Y.; Yan, T.T.; et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. *Diabetologia* 2012, 55, 2032–2043. [CrossRef]

34. Che, X.; Deng, X.; Xie, K.; Wang, Q.; Yan, J.; Shao, X.; Ni, Z.; Ying, L. Long noncoding RNA Meg3 suppresses podocyte injury in diabetic nephropathy by inactivating Wnt/β-catenin signaling. *PeerJ* 2019, 7, e8016. [CrossRef]

35. Schneider, C.; King, R.M.; Philipson, L. Genes specifically expressed at growth arrest of mammalian cells. *Cell 1988*, 54, 787–793. [CrossRef]

36. Xie, C.; Wu, W.; Tang, A.; Luo, N.; Tan, Y. IncRNA GAS5/miR-452-5p Reduces Oxidative Stress and Pyroptosis of High-Glucose-Stimulated Renal Tubular Cells. *Diabetes Metab. Syndr. Obes.* 2019, 12, 2609–2617. [CrossRef]

37. Ge, X.; Xu, B.; Xu, W.; Xia, L.; Xu, Z.; Shen, L.; Peng, W.; Huang, S. Long noncoding RNA GAS5 inhibits cell proliferation and fibrosis in diabetic nephropathy by sponging miR-221 and modulating SIRT1 expression. *Aging 2019*, 11, 8745–8759. [CrossRef]

38. Wang, W.; Jia, Y.-J.; Yang, Y.-L.; Xue, M.; Zheng, Z.-J.; Wang, L.; Xue, Y.-M. IncRNA GAS5 exacerbates renal tubular epithelial fibrosis by acting as a competing endogenous RNA of miR-96-5p. *Biomed. Pharmacother.* 2020, 121, 109411. [CrossRef]

39. Zhang, L.; Zhao, S.; Zhu, Y. Long noncoding RNA GAS5 promotes fibrosis and inflammation in diabetic nephropathy by sponging miR-96-3p. *Aging 2020*, 12, 2703–2714. [CrossRef]

40. Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Wagner, T.; Valner, S.F.; Sadashima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. *Circ. Res.* 2007, 100, 1512–1521. [CrossRef]

41. Meng, T.; Qin, W.; Liu, B. SIRT1 Antagonizes Oxidative Stress in Diabetic Vascular Complication. *Front. Endocrinol.* 2020, 11, 568661. [CrossRef]

42. Zimta, A.-A.; Tigu, A.B.; Braicu, C.; Stefan, C.; Ionescu, C.; Berindan-Neagoe, I. An Emerging Class of Long Non-coding RNA With Oncogenic Role Arises From the snoRNA Host Genes. *Front. Oncol.* 2020, 10, 389. [CrossRef]

43. Yu, M.; Ohira, M.; Li, Y.; Nizuma, H.; Oo, M.L.; Zhu, Y.; Ozaki, T.; Isogai, E.; Nakamura, Y.; Koda, T.; et al. High expression of ncRNA, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma 2. *FASEB J.* 2020, 34, 2703–2714. [CrossRef]

44. Alexendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Valner, S.F.; Sadashima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. *Circ. Res.* 2007, 100, 1512–1521. [CrossRef]

45. Jiang, X.; Ru, Q.; Li, P.; Ge, X.; Shao, K.; Xi, L.; Xu, B.; Wang, Q.; Huang, S. IncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy. *Gene Ther.* 2020, 27, 557–566. [CrossRef]

46. Zucker, S.N.; Fink, E.E.; Bagati, A.; Mannava, S.; Bianchi-Smiraglia, A.; Bogner, P.N.; Wawryniak, J.A.; Foley, L.; Leonova, K.I.; Grimm, M.J.; et al. Nrfl2 amplifies oxidative stress via induction of Ikkβ. *Mol. Cell 2014*, 53, 916–928. [CrossRef]

47. Baldini, P.; Cossu, A.; Manca, M.P.; Satta, M.; Sini, M.C.; Rozzo, C.; Dessole, S.; Cherchi, P.; Gianfrancesco, F.; Pintus, A.; et al. Identification of a novel candidate gene, CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer. *Hum. Mutat.* 2004, 23, 318–326. [CrossRef]
48. Palmieri, G.; Paliogiannis, P.; Sini, M.C.; Manca, A.; Palomba, G.; Doneddu, V.; Tanda, F.; Pascale, M.R.; Cossu, A. Long non-coding RNA CASC2 in human cancer. *Crit. Rev. Oncol. Hematol.* 2017, 111, 31–38. [CrossRef]

49. Yang, H.; Kan, Q.E.; Su, Y.; Man, H. Long Non-Coding RNA CASC2 Improves Diabetic Nephropathy by Inhibiting JNK Pathway. *Exp. Clin. Endocrinol. Diabetes* 2019, 127, 533–537. [CrossRef]

50. Min, X.Q.; Xie, Y. LncRNA CASC2 Alleviates the Progression of Diabetic Nephropathy by Regulating the miR-144/SOCS2 Signalling Axis. *Kidney Blood Press. Res.* 2020, 45, 837–849. [CrossRef]

51. Li, F.; Dai, B.; Ni, X. Long non-coding RNA cancer susceptibility candidate 2 (CASC2) alleviates the high glucose-induced injury of CHIPO-1 cells via regulating miR-9-5p/PPARy axis in diabetes nephropathy. *Diabetol. Metab. Syndr.* 2020, 12, 68. [CrossRef] [PubMed]

52. Zhang, X.-L.; Zhu, H.-Q.; Zhang, Y.; Zhang, C.-Y.; Jiao, J.-S.; Xing, X.-Y. LncRNA CASC2 regulates high glucose-induced proliferation, extracellular matrix accumulation and oxidative stress of human mesangial cells via miR-133/b/FOXp1 axis. *Eur. Rev. Med. Pharmacol. Sci.* 2020, 24, 802–812. [PubMed]

53. Monti-Rocha, R.; Cramer, A.; Leite, P.G.; Antunes, M.M.; Pereira, R.V.S.; Barroso, A.; Queiroz-Júnior, C.M.; David, B.A.; Teixeira, M.M.; Menezes, G.B.; et al. SOCS2 Is Critical for the Balancing of Immune Response and Oxidative Stress Protecting Against Acetaminophen-Induced Acute Liver Injury. *Front. Immunol.* 2018, 9, 3134. [CrossRef] [PubMed]

54. Xiang, H.; Xue, W.; Wu, X.; Zheng, J.; Ding, C.; Li, Y.; Dou, M. FOXp1 inhibits high glucose-induced ECM accumulation and oxidative stress in mesangial cells. *Chem. Biol. Interact.* 2019, 313, 108818. [CrossRef]

55. Tarquini, R.; Iazzieri, C.; Pala, L.; Rotella, C.M.; Gensini, G.F. The diabetic cardiomyopathy. *Acta Diabetol.* 2011, 48, 173–181. [CrossRef]

56. Jia, G.; Hill, M.A.; Sowers, J.R. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. *Circ. Res.* 2018, 122, 624–638. [CrossRef]

57. Li, X.; Wang, H.; Yao, B.; Xu, W.; Chen, J.; Zhou, X. LncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. *Sci. Rep.* 2016, 6, 36340. [CrossRef]

58. Kuster, G.M.; Lancel, S.; Zhang, J.; Communal, C.; Trucillo, M.P.; Lim, C.C.; Pfister, O.; Weinberg, E.O.; Cohen, R.A.; Liao, R.; et al. Redox-mediated reciprocal regulation of SERCA and Na\(^+\)-Ca\(^{2+}\) exchanger contributes to sarcoplasmic reticulum Ca\(^{2+}\) depletion in cardiac myocytes. *Free Radic. Biol. Med.* 2010, 48, 1182–1187. [CrossRef]

59. Jia, G.; Habibi, J.; Aroor, A.R.; Hill, M.A.; DeMarco, V.G.; Lee, L.E.; Ma, L.; Barron, B.J.; Whaley-Connell, A.; Sowers, J.R. Enhanced endothelial epithelial sodium channel signaling prompts left ventricular diastolic dysfunction in obese female mice. *Metabolism* 2018, 78, 69–79. [CrossRef]

60. Qu, X.; Alsager, S.; Zhuo, Y.; Shan, B. HOX transcript antisense RNA (HOTAIR) in cancer. *Cancer Lett.* 2019, 454, 90–97. [CrossRef]

61. Qi, K.; Zhong, J. LncRNA HOTAIR improves diabetic cardiomyopathy by increasing viability of cardiomyocytes through activation of the PI3K/Akt pathway. *Exp. Ther. Med.* 2018, 16, 4817–4823. [CrossRef]

62. Ren, B.C.; Zhang, Y.F.; Liu, S.S.; Cheng, X.J.; Yang, X.; Cui, X.G.; Zhao, H.; Hao, M.F.; Li, M.D.; et al. Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways. *J. Cell. Mol. Med.* 2020, 24, 12355–12367. [CrossRef]

63. Wang, X.; Zhao, L. Calycosin ameliorates diabetes-induced cognitive impairments in rats by reducing oxidative stress via the PI3K/Akt/GSK-3β signalling pathway. *Biochem. Biophys. Res. Commun.* 2016, 473, 428–434. [CrossRef]

64. Gao, L.; Wang, X.; Guo, S.; Xiao, L.; Liang, C.; Wang, Z.; Li, Y.; Liu, Y.; Yao, R.; Liu, Y.; et al. LncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR-34a in diabetic cardiomyopathy. *J. Cell. Physiol.* 2019, 234, 4944–4958. [CrossRef]

65. Chen, Y.; Huang, C.; Zhu, S.Y.; Zou, H.C.; Xu, C.Y.; Chen, Y.X. Overexpression of HOTAIR attenuates Pi-induced vascular calcification by inhibiting Wnt/β-catenin through regulating miR-126/Klotho/SIRT1 axis. *Mol. Cells. Biochem.* 2021, 476, 3551–3561. [CrossRef] [PubMed]

66. Chen, Y.; Zhang, Z.; Zhuo, W.; Li, F. Long non-coding RNA MEG3 serves as a ceRNA for microRNA-145 to induce apoptosis of AC16 cardiomyocytes under high glucose condition. *Biosci. Rep.* 2019, 39, BSR20190444. [CrossRef]

67. Hui, Y.; Yin, Y. MicroRNA-145 attenuates high glucose-induced oxidative stress and inflammation in retinal endothelial cells through regulating TLR4/NF-kB signaling. *Life Sci.* 2018, 207, 212–218. [CrossRef]

68. Feng, D.S.; Aiello, L.; Gardner, T.W.; King, G.L.; Blankenship, G.; Cavallerano, J.D.; Ferris, F.L., 3rd; Klein, R. Retinopathy in diabetes. *Diabetes Care* 2004, 27 (Suppl. 1), S84–S87. [CrossRef]

69. Thomas, A.A.; Biswas, S.; Feng, B.; Chen, S.; Gonder, J.; Chakrabarti, S. IncRNA H19 prevents endothelial-mesenchymal transition in diabetic retinopathy. *Diabetologia* 2019, 62, 517–530. [CrossRef]

70. Luo, R.; Xiao, F.; Wang, P.; Hu, Y.X. IncRNA H19 sponging miR-93 to regulate inflammation in retinal epithelial cells under hyperglycemia via XBPI1s. *Inflamm. Res.* 2020, 69, 255–265. [CrossRef]

71. Kowluru, R.A.; Tang, J.; Kern, T.S. Abnormalities of retinal metabolism in diabetes and experimental glaucoma. VII. Effect of long-term administration of antioxidants on the development of retinopathy. *Diabetes* 2001, 50, 1938–1942. [CrossRef]

72. Kowluru, R.A.; Koppolu, P.; Chakrabarti, S.; Chen, S. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. *Free Radic. Res.* 2003, 37, 1169–1180. [CrossRef]
73. Shaker, O.G.; Abdelaleem, O.O.; Mahmoud, R.H.; Abdelghaffar, N.K.; Ahmed, T.I.; Said, O.M.; Zaki, O.M. Diagnostic and prognostic role of serum miR-20b, miR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy. *IUBMB Life* **2019**, *71*, 310–320. [CrossRef]

74. Biswas, S.; Feng, B.; Chen, S.; Liu, J.; Aref-Eshghi, E.; Gonder, J.; Ngo, V.; Sadikovic, B.; Chakrabarti, S. The Long Non-Coding RNA HOTAIR Is a Critical Epigenetic Mediator of Angiogenesis in Diabetic Retinopathy. *Investig. Ophthalmol. Vis. Sci.* **2021**, *62*, 20. [CrossRef]

75. Zhao, D.; Zhao, Y.; Wang, J.; Wu, L.; Liu, Y.; Zhao, S.; Guo, F.; Ma, X.; Zhang, H.; Li, Z.; et al. Long noncoding RNA Hotair facilitates retinal endothelial cell dysfunction in diabetic retinopathy. *Clin. Sci.* **2020**, *134*, 2419–2434. [CrossRef]

76. Zhong, Q.; Kowluru, R.A. Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: Role of histone methylation. *Investig. Ophthalmol. Vis. Sci.* **2013**, *54*, 244–250. [CrossRef]

77. Yan, B.; Tao, Z.F.; Li, X.M.; Zhang, H.; Yao, J.; Jiang, Q. Aberrant expression of long noncoding RNAs in early diabetic retinopathy. *Investig. Ophthalmol. Vis. Sci.* **2014**, *55*, 941–951. [CrossRef] [PubMed]

78. Liu, J.Y.; Yao, J.; Li, X.M.; Song, Y.C.; Wang, X.Q.; Li, Y.J.; Yan, B.; Jiang, Q. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. *Cell Death Dis.* **2014**, *5*, e1506. [CrossRef] [PubMed]

79. Chen, J.; Ke, S.; Zhong, L.; Wu, J.; Tseng, A.; Morpurgo, B.; Golovko, A.; Wang, G.; Cai, J.J.; Ma, X.; et al. Long noncoding RNA MALAT1 regulates generation of reactive oxygen species and the insulin responses in male mice. *Biochem. Pharmacol.* **2018**, *152*, 94–103. [CrossRef] [PubMed]

80. Radhakrishnan, R.; Kowluru, R.A. Long Noncoding RNA MALAT1 and Regulation of the Antioxidant Defense System in Diabetic Retinopathy. *Diabetes* **2021**, *70*, 227–239. [CrossRef] [PubMed]

81. Liu, F.; Jia, S.B.; Shi, J.M.; Li, W.J.; Tang, L.S.; Zhu, X.H.; Tong, P. LncRNA-MALAT1 promotes neovascularization in diabetic retinopathy through regulating miR-125b/VE-cadherin axis. *Biosci. Rep.* **2019**, *39*, BSR20181469. [CrossRef]

82. Hou, X.; Xu, F.; Zhang, C.; Shuai, J.; Huang, Z.; Liang, Y.; Xu, X. Dexmedetomidine exerts neuroprotective effects during high glucose-induced neural injury by inhibiting miR-125b. *Biosci. Rep.* **2020**, *40*, BSR2020394. [CrossRef]

83. Gong, W.; Zhu, G.; Li, J.; Yang, X. LncRNA MALAT1 promotes the apoptosis and oxidative stress of human lens epithelial cells via p38MAPK pathway in diabetic cataract. *Diabetes Res. Clin. Pract.* **2018**, *144*, 314–321. [CrossRef]

84. Qiu, G.Z.; Tian, W.; Fu, H.T.; Li, C.P.; Liu, B. Long noncoding RNA MEG3 is involved in diabetes mellitus-related microvascular dysfunction. *Biochem. Biophys. Res. Commun.* **2016**, *471*, 135–141. [CrossRef]

85. Tu, Y.; Zhu, M.; Wang, Z.; Wang, K.; Chen, L.; Liu, W.; Shi, Q.; Zhao, Q.; Sun, Y.; Wang, X.; et al. Melatonin inhibits Müller cell activation and pro-inflammatory cytokine production via upregulating the MEG3/miR-204/Sirt1 axis in experimental diabetic retinopathy. *J. Cell. Physiol.* **2020**, *235*, 8724–8735. [CrossRef]

86. Tu, Y.; Song, E.; Wang, Z.; Ji, N.; Zhu, L.; Wang, K.; Sun, H.; Zhang, Y.; Zhu, Q.; Liu, X.; et al. Melatonin attenuates oxidative stress and inflammation of Müller cells in diabetic retinopathy via activating the Sirt1 pathway. *Biomed. Pharmacother.* **2021**, *137*, 111274. [CrossRef]

87. Luo, R.; Jin, H.; Li, L.; Hu, Y.X.; Xiao, F. Long Noncoding RNA MEG3 Inhibits Apoptosis of Retinal Pigment Epithelium Cells Induced by High Glucose via the miR-93/Nfr2 Axis. *Am. J. Pathol.* **2020**, *189*, 1813–1822. [CrossRef]

88. Tong, P.; Peng, Q.H.; Gu, L.M.; Xie, W.W.; Li, W.J. LncRNA-MEG3 alleviates high glucose induced inflammation and apoptosis of retina epithelial cells via regulating miR-34a/SIRT1 axis. *Exp. Mol. Pathol.* **2019**, *107*, 102–109. [CrossRef]

89. Cai, F.; Jiang, H.; Li, Y.; Li, Q.; Yang, C. Upregulation of long non-coding RNA SNHG16 promotes diabetes-related RMEC dysfunction via activating NF-κB and PI3K/ AKT pathways. *Nat. Ther. Nucleic Acids* **2021**, *24*, 512–527. [CrossRef]

90. Zhang, R.; Ma, X.; Jiang, L.; Xia, W.; Li, H.; Zhao, N.; Cui, X.; Zhang, N.; Zhou, H.; Xu, S. Decreased IncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis. *Curr. Pharm. Des.* **2021**, *27*, 3047–3060. [CrossRef]

91. Li, X.; Guo, C.; Chen, Y.; Yu, F. Long non-coding RNA SNHG16 regulates E2F1 expression by sponging miR-20a-5p and aggravating proliferative diabetic retinopathy. *Can. J. Physiol. Pharmacol.* **2021**, *99*, 1207–1216. [CrossRef]

92. Blanchet, E.; Annicotte, J.S.; Lagarrigue, S.; Aguilar, V.; Clapé, C.; Chavey, C.; Fritz, V.; Casas, F.; Apparailly, F.; Auwerx, J.; et al. E2F transcription factor-1 regulates oxidative metabolism via activating NF-κB and PI3K/AKT pathways. *Nat. Cell Biol.* **2011**, *13*, 1146–1152. [CrossRef]

93. Wang, Y.; Zhou, Y.; Xiao, L.; Zheng, S.; Yan, N.; Chen, D. E2F1 mediates high glucose-induced neuronal death in cultured mouse retinal explants. *Cell Cycle* **2017**, *16*, 1824–1834. [CrossRef]

94. Duraisamy, A.J.; Mohammad, G.; Kowluru, R.A. Mitochondrial fusion and maintenance of mitochondrial homeostasis in diabetic retinopathy. *Biochem. Biophys. Acta Mol. Basis Dis.* **2019**, *1865*, 1617–1626. [CrossRef]